Pravin Kumar Rao1, Sheree L Boulet2, Akanksha Mehta3, James Hotaling4, Michael L Eisenberg5, Stanton C Honig6, Lee Warner2, Dmitry M Kissin2, Ajay K Nangia7, Lawrence S Ross8. 1. Mid Atlantic Permanente Medical Group, Baltimore, Maryland. 2. Centers for Disease Control and Prevention, Atlanta, Georgia. 3. Department of Urology, Emory University, Atlanta, Georgia. 4. Division of Urology, University of Utah, Salt Lake City, Utah. 5. Department of Urology, Stanford University, Palo Alto, California. 6. Department of Urology, Yale University, New Haven, Connecticut. 7. Department of Urology, University of Kansas, Kansas City, Kansas. 8. Department of Urology, University of Illinois, Chicago, Illinois. Electronic address: lsross51941@gmail.com.
Abstract
PURPOSE: Although testosterone replacement therapy use in the United States has increased dramatically in the last decade, to our knowledge trends in testosterone replacement therapy use among reproductive-age men have not been investigated. We assessed changes in testosterone replacement therapy use and practice patterns among 18 to 45-year-old American men from 2003 to 2013 and compared them to older men. MATERIALS AND METHODS: This is a retrospective, cross-sectional analysis of men 18 to 45 and 56 to 64 years old who were enrolled in the Truven Health MarketScan® Commercial Claims Databases throughout each given calendar year from 2003 to 2013, including 5,094,868 men in 2013. Trends in the yearly rates of testosterone replacement therapy use were calculated using Poisson regression. Among testosterone replacement therapy users, the Cochran-Armitage test was used to assess temporal trends in age, formulation type, semen analysis and serum testosterone level testing during the 12 months preceding the documented use of testosterone replacement therapy. RESULTS: Between 2003 and 2013, there was a fourfold increase in the rate of testosterone use among 18 to 45-year-old men from 29.2/10,000 person-years to 118.1/10,000 person-years (p <0.0001). Among testosterone replacement therapy users, topical gel formulations were initially most used. Injection use then doubled between 2009 and 2012 (23.5% and 46.2%, respectively) and surpassed topical gel use in 2013. In men 56 to 64 years old there was a statistically significant threefold increase in testosterone replacement therapy use (p <0.0001), which was significantly smaller than the fourfold increase in younger men (p <0.0001). CONCLUSIONS: In 2003 to 2013, testosterone replacement therapy use increased fourfold in men 18 to 45 years old compared to threefold in older men. This younger age group should be a focus for future studies due to effects on fertility and unknown long-term sequelae.
PURPOSE: Although testosterone replacement therapy use in the United States has increased dramatically in the last decade, to our knowledge trends in testosterone replacement therapy use among reproductive-age men have not been investigated. We assessed changes in testosterone replacement therapy use and practice patterns among 18 to 45-year-old American men from 2003 to 2013 and compared them to older men. MATERIALS AND METHODS: This is a retrospective, cross-sectional analysis of men 18 to 45 and 56 to 64 years old who were enrolled in the Truven Health MarketScan® Commercial Claims Databases throughout each given calendar year from 2003 to 2013, including 5,094,868 men in 2013. Trends in the yearly rates of testosterone replacement therapy use were calculated using Poisson regression. Among testosterone replacement therapy users, the Cochran-Armitage test was used to assess temporal trends in age, formulation type, semen analysis and serum testosterone level testing during the 12 months preceding the documented use of testosterone replacement therapy. RESULTS: Between 2003 and 2013, there was a fourfold increase in the rate of testosterone use among 18 to 45-year-old men from 29.2/10,000 person-years to 118.1/10,000 person-years (p <0.0001). Among testosterone replacement therapy users, topical gel formulations were initially most used. Injection use then doubled between 2009 and 2012 (23.5% and 46.2%, respectively) and surpassed topical gel use in 2013. In men 56 to 64 years old there was a statistically significant threefold increase in testosterone replacement therapy use (p <0.0001), which was significantly smaller than the fourfold increase in younger men (p <0.0001). CONCLUSIONS: In 2003 to 2013, testosterone replacement therapy use increased fourfold in men 18 to 45 years old compared to threefold in older men. This younger age group should be a focus for future studies due to effects on fertility and unknown long-term sequelae.
Authors: Cindy Ke Zhou; Shailesh Advani; Matthew Chaloux; James Todd Gibson; Mandi Yu; Marie Bradley; Robert N Hoover; Michael B Cook Journal: J Urol Date: 2020-01-13 Impact factor: 7.450
Authors: Isabelle V Carter; Michael J Callegari; Tarun K Jella; Amr Mahran; Thomas B Cwalina; Wade Muncey; Aram Loeb; Nannan Thirumavalavan Journal: Int J Impot Res Date: 2022-01-07 Impact factor: 2.896
Authors: Jordan C Best; Daniel Gonzalez; Thomas A Masterson; Ruben Blachman-Braun; Raghav Pai; Ranjith Ramasamy Journal: Can Urol Assoc J Date: 2021-02 Impact factor: 1.862
Authors: David S Lopez; Danmeng Huang; Konstantinos K Tsilidis; Mohit Khera; Stephen B Williams; Randall J Urban; Orestis A Panagiotou; Yong-Fang Kuo; Jacques Baillargeon; Albert Farias; Trudy Krause Journal: Clin Endocrinol (Oxf) Date: 2019-10-07 Impact factor: 3.478
Authors: Fang Fang; Kelsey Hazegh; Derek Sinchar; Yuelong Guo; Grier P Page; Alan E Mast; Steve Kleinman; Michael P Busch; Tamir Kanias Journal: Blood Transfus Date: 2019-07 Impact factor: 3.443
Authors: Rob F Walker; Neil A Zakai; Richard F MacLehose; Logan T Cowan; Terrence J Adam; Alvaro Alonso; Pamela L Lutsey Journal: JAMA Intern Med Date: 2020-02-01 Impact factor: 21.873